Exclusive: Eli Lilly CEO David Ricks on M&A, AI and

Eli Lilly CEO David Ricks speaks exclusively to CNBC-TV18 about the drugmaker’s plans to become more acquisitive, the risks from its growing consumer exposure and why a lack of breakthrough inventions remains its biggest long-term concern. Ricks also discusses Lilly’s India manufacturing and technology ambitions, AI’s role in drug discovery and the therapeutic areas where the company sees potential for future breakthroughs.

Source